Resveratrol in management of bone and spinal cancers

Nat Prod Res. 2019 Feb;33(4):516-526. doi: 10.1080/14786419.2017.1389936. Epub 2017 Oct 20.


Bone cancer is a malignant primary tumour of the bone with different typing, such as, osteosarcoma, chondrosarcoma, Ewing's sarcoma and fibrosarcoma. Despite the clinical efficacy of conventional therapies of bone cancer, most patients eventually relapse and the disease remains incurable. Therefore, new therapeutic strategies are needed to improve patient outcome. In this review article, we have discussed the role of resveratrol in preventing bone and spinal cancers and therapeutics. Resveratrol (3,5,4'-trihydroxy-trans-stilbene) is a natural polyphenol, which has been widely reported as an anticancer molecule. Resveratrol exhibits multiple tumour-suppressing activities in bone cancer by affecting a series of critical events. It has the protective effects against oxidative injury, possesses antiproliferative activity and induces apoptosis in cancer cells. Resveratrol might be a good option for the treatment of different types of bone and spinal cancers.

Keywords: Resveratrol; apoptosis; bone cancer; oxidative stress; spinal cancer.

Publication types

  • Review

MeSH terms

  • Anticarcinogenic Agents / pharmacology*
  • Anticarcinogenic Agents / therapeutic use
  • Antineoplastic Agents, Phytogenic / pharmacology*
  • Apoptosis / drug effects
  • Bone Neoplasms / drug therapy*
  • Bone Neoplasms / pathology
  • Bone Neoplasms / prevention & control*
  • Humans
  • Osteosarcoma / drug therapy
  • Osteosarcoma / pathology
  • Resveratrol / pharmacology*
  • Sarcoma, Ewing / drug therapy
  • Sarcoma, Ewing / pathology


  • Anticarcinogenic Agents
  • Antineoplastic Agents, Phytogenic
  • Resveratrol